Subvenções e apoios para entidades sociais

NIDCD Subsídios de Pesquisa para Traduzir Pesquisa Básica em Prática Clínica (R01 Ensaio Clínico Opcional)

Estados Unidos · US

Quem pode candidatar-se Public housing authorities/Indian housing authorities · Special district governments · State governments · Public and State controlled institutions of higher education · Small businesses · Native American tribal governments (Federally recognized) · Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education · For profit organizations other than small businesses · Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education · City or township governments · Others (see text field entitled "Additional Information on Eligibility" for clarification) · Private institutions of higher education · County governments · Independent school districts · Native American tribal organizations (other than Federally recognized tribal governments)

Este Anúncio de Oportunidade de Financiamento (FOA) tem como objetivo fornecer um caminho para cientistas básicos, clínicos e cientistas clínicos iniciarem e conduzirem conjuntamente projetos de pesquisa translacional que traduzam descobertas de pesquisa básica em ferramentas clínicas para uma melhor saúde humana. O escopo deste FOA inclui uma gama de atividades para incentivar a tradução de descobertas de pesquisa básica que impactarão o diagnóstico, tratamento e prevenção de distúrbios da comunicação. A conexão com a condição clínica deve ser claramente estabelecida e os resultados da concessão devem ter impacto clínico prático.

NCI Pathway to Independence Award (K99/R00 Clinical Trial Required)

Estados Unidos · US

Quem pode candidatar-se City or township governments · Small businesses · Native American tribal organizations (other than Federally recognized tribal governments) · State governments · Others (see text field entitled "Additional Information on Eligibility" for clarification) · Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education · County governments · Native American tribal governments (Federally recognized) · Special district governments · Public housing authorities/Indian housing authorities · Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education · Independent school districts · Private institutions of higher education · For profit organizations other than small businesses · Public and State controlled institutions of higher education

O objetivo do programa NCI Pathway to Independence Award (K99/R00) é facilitar uma transição oportuna de pesquisadores de pós-doutorado talentosos com um diploma de doutorado em pesquisa e/ou clínica de posições de pesquisa pós-doutorado mentoradas para posições de corpo docente independentes, com estabilidade ou equivalentes. O programa fornecerá apoio de pesquisa independente do NCI durante esta transição para ajudar os premiados a lançar carreiras de pesquisa competitivas e independentes.

NCI Pathway to Independence Award (K99/R00 Clinical Trial Not Allowed)

Estados Unidos · US

Quem pode candidatar-se Native American tribal organizations (other than Federally recognized tribal governments) · Small businesses · Public and State controlled institutions of higher education · Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education · Native American tribal governments (Federally recognized) · Public housing authorities/Indian housing authorities · County governments · Private institutions of higher education · Others (see text field entitled "Additional Information on Eligibility" for clarification) · Special district governments · Independent school districts · Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education · State governments · For profit organizations other than small businesses · City or township governments

O objetivo do programa NCI Pathway to Independence Award (K99/R00) é facilitar uma transição oportuna de pesquisadores de pós-doutorado talentosos com um diploma de doutorado em pesquisa e/ou clínica de posições de pesquisa de pós-doutorado mentoradas para posições de corpo docente independentes, com possibilidade de efetivação ou equivalentes. O programa fornecerá apoio de pesquisa independente do NCI durante esta transição, a fim de ajudar os premiados a lançar carreiras de pesquisa independentes e competitivas.

Auxílios para compensar a paralisação temporária de atividades pesqueiras 2026 (FEMPA)

AUTONOMICA - CATALUÑA - DEPARTAMENT D'AGRICULTURA, RAMADERIA, PESCA I ALIMENTACIÓ ·

Quem pode candidatar-se PYME Y PERSONAS FÍSICAS QUE DESARROLLAN ACTIVIDAD ECONÓMICA

Agricultura, Pesca y Alimentación

Período: 9 de julho de 2026 – —

Testes em Estágio Inicial de Intervenções Farmacológicas ou Baseadas em Dispositivos de Neuromodulação para o Tratamento de Transtornos Mentais (R33 - Ensaio Clínico Necessário)

Estados Unidos · US

Quem pode candidatar-se State governments · Public housing authorities/Indian housing authorities · Special district governments · Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education · For profit organizations other than small businesses · County governments · Small businesses · Others (see text field entitled "Additional Information on Eligibility" for clarification) · Native American tribal governments (Federally recognized) · Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education · Private institutions of higher education · City or township governments · Public and State controlled institutions of higher education · Independent school districts · Native American tribal organizations (other than Federally recognized tribal governments)

O NIMH exige uma abordagem de terapêutica experimental para o desenvolvimento e teste de intervenções terapêuticas, na qual os estudos avaliam o efeito clínico de uma intervenção e geram informações sobre os mecanismos subjacentes a um transtorno ou a uma resposta à intervenção. Como parte do Pipeline de Ensaios Clínicos do NIMH, este NOFO incentiva testes em estágio inicial de intervenções farmacológicas com novos mecanismos de ação ou intervenções baseadas em dispositivos. Mais especificamente, este NOFO se destina a apoiar testes em estágio inicial de intervenções farmacológicas ou baseadas em dispositivos usando um desenho de protocolo onde o suposto mecanismo de ação da intervenção é adequadamente testado, para fornecer informações significativas onde a modulação do alvo produz um efeito neurofisiológico/clínico/comportamental dose-dependente.

Ensaios de Eficácia para Testar Intervenções no Sistema de Saúde Mental (R61/R33 Ensaio Clínico Obrigatório)

Estados Unidos · US

Quem pode candidatar-se Native American tribal governments (Federally recognized) · For profit organizations other than small businesses · State governments · Independent school districts · Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education · Public and State controlled institutions of higher education · Special district governments · Public housing authorities/Indian housing authorities · Native American tribal organizations (other than Federally recognized tribal governments) · Others (see text field entitled "Additional Information on Eligibility" for clarification) · Private institutions of higher education · Small businesses · Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education · County governments · City or township governments

Este conceito R61/R33 complementa o conjunto de NOFOs de ensaios clínicos do NIMH, apoiando o desenvolvimento de viabilidade e infraestrutura (R61) seguido por ensaios clínicos bem-sucedidos (R33) para testar a eficácia de intervenções e estratégias de sistema para melhorar a organização, entrega, coordenação e resultados clínicos e funcionais dos serviços de saúde mental. As intervenções de sistema - que podem abranger, por exemplo, domínios estruturais, políticos, organizacionais e interpessoais - abordam questões sobre o acesso, equidade, engajamento/utilização, valor (custo/financiamento), gestão ou qualidade e segurança dos serviços de saúde mental, com o objetivo de melhorar os processos de cuidado e os resultados clínicos e funcionais. Consequentemente, o foco das intervenções de sistema pode incluir uma variedade de ambientes de cuidado, como sistemas e organizações de saúde, clínicas de saúde mental e comunitárias, escolas e sistemas de bem-estar infantil ou justiça juvenil.

Ensaios de Eficácia-Implementação Híbridos em Grande Escala para Intervenções de Saúde Mental (R01 - Ensaio Clínico Obrigatório)

Estados Unidos · US

Quem pode candidatar-se Native American tribal governments (Federally recognized) · Native American tribal organizations (other than Federally recognized tribal governments) · Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education · State governments · Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education · Small businesses · Public and State controlled institutions of higher education · County governments · Others (see text field entitled "Additional Information on Eligibility" for clarification) · City or township governments · Public housing authorities/Indian housing authorities · Special district governments · Independent school districts · Private institutions of higher education · For profit organizations other than small businesses

Ensaios Clínicos para Testar a Eficácia de Intervenções de Tratamento, Prevenção e Serviços (R01 Ensaio Clínico Obrigatório). Este NOFO é um elemento chave do conjunto de NOFOs do NIMH para apoiar a pesquisa de ensaios clínicos em todo o pipeline de desenvolvimento e teste de intervenções. O NOFO apoia (1) ensaios clínicos para testar a eficácia de intervenções terapêuticas e preventivas otimizadas para uso em ambientes comunitários e de prática; e (2) ensaios clínicos para avaliar a eficácia de intervenções de serviços em nível de paciente, provedor, organizacional ou de sistemas para melhorar o acesso, a continuidade, a qualidade, a equidade e/ou o valor dos serviços de saúde mental. Este NOFO destina-se a apoiar ensaios que: abordem um problema significativo, de modo que os achados tenham potencial para informar a prática; sejam adequadamente dimensionados para responder definitivamente às questões de pesquisa primárias, com hipóteses bem justificadas apoiadas por dados piloto; e sejam projetados para examinar questões relativas a mediadores e moderadores de efeitos. Consistente com a abordagem de terapêutica experimental do NIMH, este NOFO destina-se a apoiar ensaios de eficácia que abordem explicitamente se a intervenção engaja o(s) alvo(s)/mecanismo(s) presumido(s) para sustentar os efeitos da intervenção (ou seja, o(s) mecanismo(s) que explica(m) as mudanças nos resultados clínicos/funcionais, mudanças no comportamento do provedor, melhor acesso ou continuidade dos serviços, etc.). O mecanismo colaborativo R01 fornece suporte para ensaios multicêntricos quando dois ou…

Desenvolvimento de Intervenções Terapêuticas e Preventivas Psicossociais para Transtornos Mentais (R33 Ensaio Clínico Obrigatório)

Estados Unidos · US

Quem pode candidatar-se Others (see text field entitled "Additional Information on Eligibility" for clarification) · Special district governments · Native American tribal governments (Federally recognized) · Private institutions of higher education · Small businesses · City or township governments · Public housing authorities/Indian housing authorities · County governments · Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education · Native American tribal organizations (other than Federally recognized tribal governments) · Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education · Independent school districts · State governments · Public and State controlled institutions of higher education · For profit organizations other than small businesses

Desenvolvimento de Intervenções Terapêuticas e Preventivas Psicossociais para Transtornos Mentais (R33 Ensaio Clínico Obrigatório). Como parte do pipeline de ensaios clínicos do NIMH, este NOFO incentiva a pesquisa piloto que desenvolve e testa novas intervenções psicossociais e/ou alvos. Consistente com a ênfase do NIMH na abordagem de terapêutica experimental para o desenvolvimento de intervenções, ele pretende acelerar a tradução de pesquisas emergentes em ciência básica, comportamental, cognitiva, afetiva e neuropsicológica em intervenções preventivas ou terapêuticas. Esta RFA fornecerá até três anos de apoio para replicar o engajamento do alvo de estudos anteriores e para testar a associação entre o engajamento do alvo e a mudança nos resultados clínicos.

Ensaios Piloto Híbridos de Eficácia-Implementação para Intervenções de Saúde Mental (R01 Ensaio Clínico Obrigatório)

Estados Unidos · US

Quem pode candidatar-se Special district governments · Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education · County governments · Independent school districts · For profit organizations other than small businesses · Small businesses · Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education · Others (see text field entitled "Additional Information on Eligibility" for clarification) · City or township governments · Public and State controlled institutions of higher education · Native American tribal organizations (other than Federally recognized tribal governments) · Public housing authorities/Indian housing authorities · Private institutions of higher education · State governments · Native American tribal governments (Federally recognized)

Ensaios Piloto de Eficácia para Intervenções de Tratamento, Prevenção e Serviços (R01 Ensaio Clínico Obrigatório). Como parte dos NOFOs do pipeline de ensaios clínicos do NIMH, este anúncio incentiva estudos piloto de eficácia focados em 1) otimizar a eficácia de intervenções preventivas e terapêuticas com eficácia previamente demonstrada, para uso com populações-alvo mais amplas ou para uso em ambientes de prática comunitária, e 2) desenvolver e testar preliminarmente intervenções de serviços inovadoras. Consistente com a abordagem de terapêutica experimental do NIMH, este NOFO destina-se a apoiar estudos piloto de eficácia de intervenção ou abordagens de prestação de serviços que abordem explicitamente se a intervenção envolve o(s) alvo(s)/mecanismo(s) presumido(s) para sustentar os efeitos da intervenção (ou seja, o(s) mecanismo(s) que explica(m) as mudanças nos resultados clínicos/funcionais, mudanças no comportamento do provedor, melhor acesso ou continuidade dos serviços, etc.).

Ensaios Clínicos Confirmatórios de Eficácia de Intervenções Não Farmacológicas e Farmacológicas para Transtornos Mentais (R01 Ensaio Clínico Obrigatório)

Estados Unidos · US

Quem pode candidatar-se Others (see text field entitled "Additional Information on Eligibility" for clarification) · City or township governments · Public housing authorities/Indian housing authorities · For profit organizations other than small businesses · Small businesses · Independent school districts · Native American tribal governments (Federally recognized) · Native American tribal organizations (other than Federally recognized tribal governments) · Private institutions of higher education · Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education · Special district governments · State governments · County governments · Public and State controlled institutions of higher education · Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education

Ensaios Clínicos Confirmatórios de Eficácia de Intervenções Não Farmacológicas para Transtornos Mentais (R01 Ensaio Clínico Obrigatório). Como parte dos NOFOs do pipeline de ensaios clínicos do NIMH, este anúncio apoia testes de eficácia confirmatórios de intervenções terapêuticas e preventivas não farmacológicas para transtornos mentais em adultos e crianças que abordam necessidades terapêuticas não atendidas e são consistentes com a ênfase do NIMH na abordagem de terapêutica experimental. Nesta abordagem, os ensaios clínicos devem ser projetados para aumentar o conhecimento da relação entre os processos subjacentes da doença e os mecanismos de ação através dos quais qualquer intervenção produz mudança terapêutica.

Desenvolvimento de Intervenções Terapêuticas e Preventivas Psicossociais para Transtornos Mentais (R61/R33 Ensaio Clínico Obrigatório)

Estados Unidos · US

Quem pode candidatar-se Native American tribal organizations (other than Federally recognized tribal governments) · Others (see text field entitled "Additional Information on Eligibility" for clarification) · Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education · Private institutions of higher education · Public and State controlled institutions of higher education · Small businesses · Independent school districts · Public housing authorities/Indian housing authorities · County governments · State governments · Native American tribal governments (Federally recognized) · For profit organizations other than small businesses · City or township governments · Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education · Special district governments

Desenvolvimento de Intervenções Terapêuticas e Preventivas Psicossociais para Transtornos Mentais (R61/R33 Ensaio Clínico Obrigatório). Como parte do pipeline de ensaios clínicos do NIMH, este NOFO incentiva a pesquisa piloto que desenvolve e testa novas intervenções psicossociais e/ou alvos. Consistente com a ênfase do NIMH na abordagem de terapêutica experimental para o desenvolvimento de intervenções, ele pretende acelerar a tradução de pesquisas emergentes em ciência básica, comportamental, cognitiva, afetiva e neuropsicológica em intervenções preventivas ou terapêuticas. Esta RFA fornecerá até dois anos de apoio para avaliação do engajamento do alvo e estabelecimento de parâmetros de intervenção, e até três anos de apoio para replicar o engajamento do alvo de estudos anteriores e para testar a associação entre o engajamento do alvo e a mudança nos resultados clínicos.

Primeiros Ensaios Clínicos em Humanos e Estágio Inicial de Novas Drogas Investigacionais ou Intervenções Baseadas em Dispositivos Neuromoduladores para Transtornos Psiquiátricos (U01 Ensaio Clínico Obrigatório)

Estados Unidos · US

Quem pode candidatar-se Native American tribal organizations (other than Federally recognized tribal governments) · Small businesses · Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education · Special district governments · Others (see text field entitled "Additional Information on Eligibility" for clarification) · Public and State controlled institutions of higher education · Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education · County governments · Independent school districts · City or township governments · Native American tribal governments (Federally recognized) · Public housing authorities/Indian housing authorities · For profit organizations other than small businesses · Private institutions of higher education · State governments

O objetivo desta Notificação de Oportunidade de Financiamento (NOFO) é incentivar aplicações de acordos cooperativos para apoiar ensaios clínicos em estágio inicial de novos mecanismos de ação, drogas investigacionais ou novos dispositivos neuromoduladores para o tratamento de transtornos psiquiátricos em áreas de necessidade médica não atendida. A NOFO apoiará ensaios em estágio inicial orientados por marcos em populações pediátricas e adultas. Estudos de primeira vez em humanos (FIH) e Fase II de novos agentes devem avaliar o engajamento do alvo (exposição cerebral), efeitos farmacológicos, segurança e tolerabilidade para avaliar a viabilidade para estudos de Fase II/prova de conceito (PoC) em transtornos psiquiátricos. Estudos de Fase II/PoC devem avaliar o impacto das drogas em sistemas fisiológicos clinicamente relevantes (medidas funcionais) e indicadores clínicos de efeito. A NOFO também apoia estudos FIH e de viabilidade inicial (EFS) de novos dispositivos para avaliar o engajamento do alvo, segurança, tolerabilidade e eficácia. O objetivo geral é facilitar a rápida coleta de dados para "desarriscar" drogas investigacionais com novos mecanismos de ação, novas drogas para uso em populações pediátricas com transtornos psiquiátricos e dispositivos ou tratamentos combinados, a fim de atrair financiamento privado ou outro financiamento público para o desenvolvimento clínico posterior como tratamentos aprovados pela FDA. Um aspecto chave desta NOFO é a formação de parcerias colaborativas entre pesquisadores biomédicos e pesquisadores de biotecnologia ou da indústria para facilitar o desenvolvimento de drogas ou dispositivos psiquiátricos…

Teste em Estágio Inicial de Intervenções Farmacológicas ou Baseadas em Dispositivos de Neuromodulação para o Tratamento de Transtornos Mentais (R61/R33 Ensaio Clínico Obrigatório)

Estados Unidos · US

Quem pode candidatar-se Native American tribal governments (Federally recognized) · Independent school districts · City or township governments · State governments · Small businesses · Public housing authorities/Indian housing authorities · Native American tribal organizations (other than Federally recognized tribal governments) · Public and State controlled institutions of higher education · For profit organizations other than small businesses · Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education · Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education · County governments · Special district governments · Private institutions of higher education · Others (see text field entitled "Additional Information on Eligibility" for clarification)

O NIMH exige uma abordagem de terapêutica experimental para o desenvolvimento e teste de intervenções terapêuticas, na qual os estudos avaliam o efeito clínico de uma intervenção e geram informações sobre os mecanismos subjacentes a um transtorno ou a uma resposta à intervenção. Como parte do Pipeline de Ensaios Clínicos do NIMH, este NOFO incentiva o teste em estágio inicial de intervenções farmacológicas com novos mecanismos de ação ou intervenções baseadas em dispositivos. Mais especificamente, este NOFO destina-se a apoiar o teste em estágio inicial de intervenções farmacológicas ou baseadas em dispositivos usando um desenho de protocolo onde o suposto mecanismo de ação da intervenção é adequadamente testado, para fornecer informações significativas onde a modulação do alvo produz um efeito neurofisiológico/clínico/comportamental dose-dependente.

NIDCD Early Career Research(ECR) Award (R21 Clinical Trial Optional)

Estados Unidos · US

Quem pode candidatar-se Native American tribal governments (Federally recognized) · City or township governments · Others (see text field entitled "Additional Information on Eligibility" for clarification) · Public and State controlled institutions of higher education · Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education · County governments · Public housing authorities/Indian housing authorities · Native American tribal organizations (other than Federally recognized tribal governments) · For profit organizations other than small businesses · State governments · Small businesses · Special district governments · Private institutions of higher education · Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education · Independent school districts

The NIDCD Early Career Research (ECR) Award (R21) is intended to support both basic and clinical research from scientists who are beginning to establish an independent research career. It cannot be used for thesis or dissertation research. The research must be focused on one or more of the areas within the biomedical and behavioral scientific mission of the NIDCD: hearing, balance, smell, taste, voice, speech, or language. The NIDCD ECR Award R21 grant mechanism supports different types of projects including secondary analysis of existing data; small, self-contained research projects; development of research methodology; translational research; outcomes research; and development of new research technology. Irrespective of the type of project, the intent of the NIDCD ECR Award R21 is for the Program Director(s)/Principal Investigator(s) (PD(s)/PI(s)) to obtain sufficient preliminary data for a subsequent R01 application.

NEI Research Grant for Vision-Related Secondary Data Analysis (R21 Clinical Trial Not Allowed)

Estados Unidos · US

Quem pode candidatar-se Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education · For profit organizations other than small businesses · Private institutions of higher education · Small businesses · Special district governments · Independent school districts · Public and State controlled institutions of higher education · Native American tribal governments (Federally recognized) · State governments · Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education · Others (see text field entitled "Additional Information on Eligibility" for clarification) · County governments · Native American tribal organizations (other than Federally recognized tribal governments) · Public housing authorities/Indian housing authorities · City or township governments

The goal of this funding opportunity announcement (FOA) is to fund meritorious vision-related research projects that involve secondary data analyses using existing database resources. The development of statistical methodology necessary for improving methods to analyze vision health data using existing vision data may also be proposed.

NIDCD Cooperative Agreement for Clinical Trials in Communication Disorders (U01 - Clinical Trial Required)

Estados Unidos · US

Quem pode candidatar-se Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education · Native American tribal organizations (other than Federally recognized tribal governments) · City or township governments · Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education · Others (see text field entitled "Additional Information on Eligibility" for clarification) · Small businesses · Native American tribal governments (Federally recognized) · For profit organizations other than small businesses · State governments · Private institutions of higher education · Special district governments · Public housing authorities/Indian housing authorities · Public and State controlled institutions of higher education · County governments · Independent school districts

The NIDCD is committed to identifying effective interventions for the treatment or prevention of communication disorders by supporting well designed and well executed clinical trials. This funding opportunity announcement (FOA) supports a cooperative agreement between an NIDCD Project Scientist and an investigator to support a clinical trial that meets ANY of the following criteria: requires FDA oversight, is intended to formally establish efficacy, or has a higher risk to potentially cause physical or psychological harm.

Early-Stage Development of Informatics Technologies for Cancer Research and Management (U01 Clinical Trial Optional)

Estados Unidos · US

Quem pode candidatar-se Public and State controlled institutions of higher education · Independent school districts · For profit organizations other than small businesses · Small businesses · Public housing authorities/Indian housing authorities · Others (see text field entitled "Additional Information on Eligibility" for clarification) · Native American tribal governments (Federally recognized) · City or township governments · Native American tribal organizations (other than Federally recognized tribal governments) · Special district governments · Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education · County governments · State governments · Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education · Private institutions of higher education

This Notice of Funding Opportunity (NOFO) solicits applications for the development of enabling informatics technologies to improve the acquisition, management, analysis, and dissemination of data and knowledge across the cancer research continuum including cancer biology, cancer treatment and diagnosis, early cancer detection, risk assessment and prevention, cancer control and epidemiology. As a component of the NCI's Informatics Technology for Cancer Research (ITCR) Program, this NOFO is focused on early-stage development from prototyping to initial dissemination. Early-stage development is defined for the purpose of this NOFO as initial tool development or the significant modification of existing tools for new applications. The central mission of ITCR is to promote research-driven informatics technology across the development lifecycle to address priority needs in cancer research. In order to be successful, proposed development plans must have a clear rationale for why the proposed technology is needed and how it will benefit the cancer research field. In addition, mechanisms to solicit feedback from driving research projects and other users throughout the development process must be included.This NOFO encourages applications that involve the development of new, user-friendly informatics technologies that support a wide range of cancer research, including discovery biology, population studies, as well as clinical and translational research. The emphasis is on uniqueness and potential impact on cancer research. In addition, all projects proposed in response to this NOFO must involve the following general attributes:Potential to advance driving cancer research projects and the cancer research field in generalNovel informatics capabilities for the targeted cancer research domainCompelling plans and processes for engaging end users to evaluate and apply the tool or resourceA realistic timeline and milestones for technology development

Competição Limitada: Clinical and Translational Science Award (CTSA) Program: Collaborative and Innovative Acceleration Award (UG3/UH3 Clinical Trial Optional)

Estados Unidos · US

Quem pode candidatar-se Public and State controlled institutions of higher education

O CTSA Collaborative and Innovative Acceleration Award (CCIA) visa acelerar o ritmo da pesquisa translacional ao apoiar o desenvolvimento colaborativo, a disseminação e a implementação sustentável de soluções inovadoras através do CTSA Program Consortium e além. Este Notice of Funding Opportunity (NOFO) convida candidaturas iniciadas por investigadores para desenvolver, demonstrar e disseminar novas abordagens, tecnologias, recursos ou modelos inovadores que aumentem o impacto da pesquisa em diversas doenças, transformem o campo da ciência translacional e tragam mais tratamentos para todas as pessoas de forma mais rápida.

Innovation Grants to Nurture Initial Translational Efforts (IGNITE): Neurotherapeutic Agent Characterization and In vivo Efficacy Studies (R61/R33 Clinical Trial Not Allowed)

Estados Unidos · US

Quem pode candidatar-se For profit organizations other than small businesses · Public housing authorities/Indian housing authorities · Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education · Native American tribal governments (Federally recognized) · Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education · Private institutions of higher education · Public and State controlled institutions of higher education · Independent school districts · City or township governments · State governments · Special district governments · County governments · Small businesses · Native American tribal organizations (other than Federally recognized tribal governments) · Others (see text field entitled "Additional Information on Eligibility" for clarification)

Reissue PAR-21-122. This NOFO provides funding to conduct pharmacodynamic, pharmacokinetic, and in vivo efficacy studies to demonstrate that proposed therapeutic agent(s) have sufficient biological activity to warrant further development to treat neurological or neuromuscular disorders that fall under the NINDS mission. Therapeutic agents include small molecules, biologics or biotechnology-derived products. This FOA is part of a suite of Innovation Grants to Nurture Initial Translational Efforts (IGNITE) to advance projects to the point where they can meet the entry criteria for the Blueprint Neurotherapeutics Network or other translational programs.

Innovation Grants to Nurture Initial Translational Efforts (IGNITE): Assay Development and Neurotherapeutic Agent Identification (R61/R33 Clinical Trial Not Allowed)

Estados Unidos · US

Quem pode candidatar-se Special district governments · City or township governments · Independent school districts · Public housing authorities/Indian housing authorities · For profit organizations other than small businesses · Native American tribal organizations (other than Federally recognized tribal governments) · Others (see text field entitled "Additional Information on Eligibility" for clarification) · Small businesses · Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education · Private institutions of higher education · County governments · Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education · State governments · Public and State controlled institutions of higher education · Native American tribal governments (Federally recognized)

This funding opportunity announcement (FOA) encourages research grant applications to develop in vitro and/or ex vivo assays and conduct iterative screening efforts to identify and characterize potential therapeutic agents for neurological or neuromuscular disorders. This FOA is part of a suite of Innovation Grants to Nurture Initial Translational Efforts (IGNITE) to advance projects to the point where they can meet the entry criteria for the Blueprint Neurotherapeutics Network (BPN) or other translational programs.

Innovation Grants to Nurture Initial Translational Efforts (IGNITE): Development and Validation of Model Systems to Facilitate Neurotherapeutic Discovery (R61/R33 Clinical Trial Not Allowed)

Estados Unidos · US

Quem pode candidatar-se Small businesses · For profit organizations other than small businesses · Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education · State governments · City or township governments · Native American tribal organizations (other than Federally recognized tribal governments) · Public housing authorities/Indian housing authorities · County governments · Independent school districts · Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education · Private institutions of higher education · Others (see text field entitled "Additional Information on Eligibility" for clarification) · Special district governments · Public and State controlled institutions of higher education · Native American tribal governments (Federally recognized)

This funding opportunity announcement (FOA) encourages the development and validation of animal models and human/animal tissue ex vivo systems that recapitulate the phenotypic and physiologic characteristics of a defined neurological or neuromuscular disorder. The goal of this FOA is to promote a significant improvement in the translational relevance of animal models or ex vivo systems that will be utilized to facilitate future development of neurotherapeutics. Ideally, models proposed for this FOA would have the potential to provide feasible and meaningful assessments of efficacy following therapeutic intervention that would be applicable in both preclinical and clinical settings. This FOA is part of a suite of Innovation Grants to Nurture Initial Translational Efforts (IGNITE) Program focused on enabling the exploratory and early stages of drug discovery.

Research Enhancement Award Program (REAP) for Health Professional Schools and Graduate Schools (R15 Clinical Trial Required)

Estados Unidos · US

Quem pode candidatar-se Private institutions of higher education · Public and State controlled institutions of higher education

The purpose of the Research Enhancement Award Program (REAP) for Health Professional Schools and Graduate Schools is to support small scale research grants at institutions that do not receive substantial funding from the NIH, with an emphasis on providing biomedical research experiences primarily for health professional, undergraduate and graduate students and enhancing the research environment at applicant institutions.Eligible institutions must award baccalaureate or advanced science degrees and have received no more than $6 million dollars per year of NIH support (in both direct and F&A/indirect costs) in 4 of the last 7 fiscal years. For institutions composed of multiple schools and colleges, the $6 million funding limit is based on the amount of NIH funding received by all the schools and colleges within the institution as a whole.Help determining the Organization Funding Level can be found here or https://grants.nih.gov/grants/funding/r15.htmThis REAP Notice of Funding Opportunity (NOFO) supports investigator-initiated mechanistic and/or minimal risk clinical trials addressing the mission and research interests of the participating NIH institutes. For purposes of this NOFO, minimal risk clinical trials are defined as those that do not require FDA oversight, do not intend to formally establish efficacy, and have low risks to potentially cause physical or psychological harm.

National Cooperative Drug/Device Discovery/Development Groups (NCDDG) for the Treatment of Mental Disorders (U19 Clinical Trial Optional)

Estados Unidos · US

Quem pode candidatar-se Public and State controlled institutions of higher education · Native American tribal organizations (other than Federally recognized tribal governments) · Native American tribal governments (Federally recognized) · Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education · Independent school districts · Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education · For profit organizations other than small businesses · County governments · Public housing authorities/Indian housing authorities · Others (see text field entitled "Additional Information on Eligibility" for clarification) · Private institutions of higher education · Special district governments · State governments · Small businesses · City or township governments

Reissue of PAR-20-119. This FOA encourages applications to advance the discovery, preclinical development, and proof of concept (PoC) testing of new, rationally based candidate agents and neurostimulation approaches to treat mental disorders, substance use disorders (SUDs) or alcohol use disorder (AUD), and to develop novel ligands and circuit-engagement devices as tools to further characterize existing or to validate new drug/device targets. Partnerships between academia and industry are strongly encouraged. This FOA supports a research program of multiple projects directed toward a specific major objective, basic theme or program goal, requiring a broadly based, multidisciplinary and often long-term approach. Projects seeking support for a discrete, specified, circumscribed project to be performed by the named investigator(s) in an area representing his or her specific interest and competencies should consider the companion U01 FOA.

National Cooperative Drug/Device Discovery/Development Groups (NCDDG) for the Treatment of Mental Disorders (U01 Clinical Trial Optional)

Estados Unidos · US

Quem pode candidatar-se Public housing authorities/Indian housing authorities · Native American tribal organizations (other than Federally recognized tribal governments) · For profit organizations other than small businesses · Special district governments · Small businesses · Others (see text field entitled "Additional Information on Eligibility" for clarification) · City or township governments · County governments · State governments · Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education · Native American tribal governments (Federally recognized) · Private institutions of higher education · Independent school districts · Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education · Public and State controlled institutions of higher education

Reissue of PAR-20-118. This Notice of Funding Opportunity (NOFO) encourages applications to advance the discovery, preclinical development, and proof of concept (PoC) testing of new, rationally based candidate agents and neurostimulation approaches to treat mental disorders, substance use disorders (SUDs) or alcohol use disorder (AUD), and to develop novel ligands and circuit-engagement devices as tools to further characterize existing or to validate new drug/device targets. Partnerships between academia and industry are strongly encouraged. This NOFO using the U01 mechanism supports a discrete, specified, circumscribed project to be performed by the named investigator(s) in an area representing his or her specific interest and competencies Projects seeking support for a research program of multiple projects directed toward a specific major objective, basic theme or program goal, requiring a broadly based, multidisciplinary and often long-term approach should consider the companion U19 FOA.